Program
Omeprazole
Also written as “Atazanavir/Ritonavir+Omeprazole”, “omeprazole” and “Omeprazole 20 mg”.
Its studies are mostly in Gastroesophageal Reflux · Neoplasms · Laryngopharyngeal Reflux · Heartburn · HIV Infections, led by 13 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 90 open or running | phase 4since Mar 18, 2008 | Nov 20, 2005 | none ahead |
| Bayer | 40 open or running | phase 4since Apr 4, 2012 | May 2, 2008 | none ahead |
| Dr. Reddy's Laboratories | 40 open or running | phase 1since Jan 8, 2010 | Jan 8, 2010 | none ahead |
| Boehringer Ingelheim | 30 open or running | phase 1since Sep 30, 2014 | Sep 30, 2014 | none ahead |
| GlaxoSmithKline | 20 open or running | phase 1since Mar 1, 2007 | Mar 1, 2007 | none ahead |
| Procter and Gamble | 20 open or running | phase 4since Dec 15, 2008 | Dec 15, 2008 | none ahead |
| Sanofi | 20 open or running | phase 3since Sep 2, 2009 | Sep 2, 2009 | none ahead |
| AbbVie | 10 open or running | phase 3since Apr 29, 2008 | Apr 29, 2008 | none ahead |
| ascension-health | 10 open or running | phase 4since Jan 25, 2013 | Jan 25, 2013 | none ahead |
| nekkar-lab-srl | 11 open or running | no phasesince Oct 14, 2019 | Oct 14, 2019 | none ahead |
| perle-bioscience-inc | 10 open or running | phase 3since Jan 2, 2013 | Jan 2, 2013 | none ahead |
| pt-kalbe-farma-tbk | 10 open or running | no phasesince Feb 8, 2023 | Feb 8, 2023 | none ahead |
| SD Biosensor | 10 open or running | phase 4since Jan 19, 2009 | Jan 19, 2009 | none ahead |
Also a collaborator on its studies: pt-pharma-metric-labs, parexel, medpace-inc, syreon-corporation, Bausch Health Companies, Ferring Pharmaceuticals and Tanabe Pharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 18 studies since Nov 20, 2005.
- Apr 15, 2011Phase 1 study in HeartburnBayer · NCT01337804 · 50 enrolled
- Feb 10, 2012Phase 1 study in Carcinoma, MedullarySanofi · NCT01539655 · 34 enrolled · United States
- Apr 4, 2012Phase 4 study in HeartburnBayer · NCT01587885 · 48 enrolled
- Jan 2, 2013perle-bioscience-inc's first study: phase 3 study in Diabetes Mellitus, Type 1New to perle-bioscience-incperle-bioscience-inc · NCT01762644
- Jan 25, 2013ascension-health's first study: phase 4 study in Laryngopharyngeal RefluxNew to ascension-healthascension-health · NCT01777854 · 6 enrolled · United States
- Aug 5, 2013Phase 1 study in Bioequivalence, AUC, Cmax, PharmacokineticsAstraZeneca · NCT01921920 · 54 enrolled · United States
- Sep 30, 2014Boehringer Ingelheim's first study: phase 1 study in HealthyNew to Boehringer IngelheimBoehringer Ingelheim · NCT02253875 · 15 enrolled
- Jan 20, 2015Phase 1 study in HealthyBoehringer Ingelheim · NCT02345304 · Germany
- May 21, 2015Phase 1 study in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT02453022 · 18 enrolled · United States
- Oct 14, 2019nekkar-lab-srl's first study: no phase study in Gastroesophageal RefluxNew to nekkar-lab-srlnekkar-lab-srl · NCT04130659 · 110 planned · Italy, Romania
- Jun 8, 2021Phase 1 study in Advanced Solid TumoursAstraZeneca · NCT04959266 · 5 enrolled · United States, Spain
- Apr 1, 2022Phase 1 study in HealthyAstraZeneca · NCT05319912 · 18 enrolled · United States
- Feb 8, 2023pt-kalbe-farma-tbk's first study: no phase study in Drug UseNew to pt-kalbe-farma-tbkpt-kalbe-farma-tbk · NCT05849883 · 36 enrolled · Indonesia
- Feb 14, 2023No phase study in Liver CirrhosisBoehringer Ingelheim · NCT05741385 · 4 enrolled · Germany
TargetBeta
“Potassium-transporting ATPase inhibitor; Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Esomeprazolerule | AstraZeneca | phase 4 | 129 |
| Rabeprazolerule | Eisai | phase 4 | 66 |
| tegoprazanrule | HK inno.N | phase 4 | 48 |
| vonoprazanrule | Takeda | phase 4 | 48 |
| fexuprazanrule | Daewoong Pharmaceutical | phase 4 | 29 |
Studies
All 32 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05741385Liver Cirrhosis · Germany | – | Completed | Boehringer Ingelheim | Aug 9, 2024 | 4 |
| NCT05849883Drug Use · Indonesia | – | Completed | pt-kalbe-farma-tbk | Jan 14, 2021 | 36 |
| NCT05319912Healthy · United States | 1 | Completed | AstraZeneca | May 29, 2014 | 18 |
| NCT04959266Advanced Solid Tumours · United States, Spain | 1 | Terminated | AstraZeneca | Jun 1, 2022 | 5 |
| NCT04130659Gastroesophageal Reflux · Italy, Romania | – | Recruiting | nekkar-lab-srl | Dec 31, 2024 | 110 |
| NCT02453022Pulmonary Disease, Chronic Obstructive · United States | 1 | Completed | GlaxoSmithKline | Jul 31, 2015 | 18 |
| NCT02345304Healthy · Germany | 1 | Withdrawn | Boehringer Ingelheim | Apr 2015 | 0 |
| NCT02253875Healthy | 1 | Completed | Boehringer Ingelheim | Feb 2006 | 15 |
| NCT01921920Bioequivalence, AUC, Cmax, Pharmacokinetics · United States | 1 | Completed | AstraZeneca | Nov 2013 | 54 |
| NCT01777854Laryngopharyngeal Reflux · United States | 4 | Terminated | ascension-health | Jul 2015 | 6 |
| NCT01762644Diabetes Mellitus, Type 1 | 3 | Withdrawn | perle-bioscience-inc | May 2016 | 0 |
| NCT01587885Heartburn | 4 | Completed | Bayer | Apr 2012 | 48 |
| NCT01539655Carcinoma, Medullary · United States | 1 | Completed | Sanofi | Sep 2012 | 34 |
| NCT01337804Heartburn | 1 | Completed | Bayer | Jan 2011 | 50 |
| NCT01159145Pharmacodynamics Study · Japan | 1 | Completed | AstraZeneca | Sep 2010 | 42 |
| NCT01170182Healthy | 1 | Completed | Dr. Reddy's Laboratories | Apr 2006 | 54 |
| NCT01170169Healthy | 1 | Completed | Dr. Reddy's Laboratories | Mar 2006 | 44 |
| NCT01045642Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Dec 2006 | 38 |
| NCT01045434Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Jan 2007 | 62 |
| NCT00971581Pain · Mexico | 3 | Completed | Sanofi | May 2010 | 52 |
| NCT00903448Healthy · United States | 4 | Completed | Procter and Gamble | Jun 2009 | 40 |
| NCT00825630Helicobacter Pylori Infection · Israel | 4 | Completed | SD Biosensor | Nov 2009 | 123 |
| NCT00808769Normal Healthy Subject Population · United States | 4 | Completed | Procter and Gamble | Dec 2008 | 30 |
| NCT00765206Gastric Acid | 3 | Completed | Bayer | Aug 2008 | 60 |
| NCT00674115Gastric Acid | 3 | Completed | Bayer | Jun 2008 | 60 |
| NCT00669955Helicobacter Infections · United Kingdom | 3 | Completed | AbbVie | Jul 2009 | 440 |
| NCT00641264Laryngopharyngeal Reflux | 4 | Completed | AstraZeneca | Jun 2003 | 90 |
| NCT00443170Anemia · Australia | 1 | Completed | GlaxoSmithKline | 90 | |
| NCT00402259Gastrointestinal Hemorrhage · China | 3 | Completed | AstraZeneca | 440 | |
| NCT00259077Non-Erosive Reflux Disease · Japan | 3 | Completed | AstraZeneca | Jul 2004 | 270 |
| NCT00259051Non-Erosive Reflux Disease · Japan | 3 | Completed | AstraZeneca | Aug 2004 | 40 |
| NCT00256737Gastroesophageal Reflux · Denmark, Finland, Norway and more | 3 | Completed | AstraZeneca | Oct 2005 | 219 |
How it is read
Names in the registry
- “Omeprazole”, 30 entries
- “Atazanavir/Ritonavir+Omeprazole”, 4 entries
- “omeprazole”, 3 entries
- “Omeprazole 20 mg”, 2 entries
- “Omeprazole/sodium bicarbonate”, 2 entries
Conditions, from the studies’ own filings
- Gastroesophageal Reflux, 3 studies
- Neoplasms, 2 studies
- Laryngopharyngeal Reflux, 2 studies
- Heartburn, 2 studies
- HIV Infections, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.